Iron sucrose-labeled human mesenchymal stem cells: in vitro multilineage capability and in vivo traceability in a lapine xenotransplantation model.

For evaluation of cell therapy applications, it is of interest to be able to trace and observe cellular distribution of the transplanted cells. The aim with the study was to examine viability, traceability, and multilineage capability of iron sucrose-labeled mesenchymal stem cells (MSCs) after transplantation into lapine intervertebral discs (IVDs). MSCs were collected from three human donors, age 31-50 years, and IVDs from 12 rabbits, age 3 months. MSCs were isolated from the bone marrow and cultured using standard protocols. Iron sucrose labeling of MSCs was performed in Dulbecco's Modified Eagle's Medium-low glucose with Venofer(®). The iron sucrose-labeled MSCs were differentiated into the adipogenic, osteogenic, and chondrogenic lineages. Results were evaluated using Oil red, von Kossa, Alcian blue, and collagen II (immunohistochemistry). For the animal experiments, iron sucrose-labeled MSCs and nonlabeled MSCs were injected into lapine IVDs (LI-LIV level). After transplantation, at the time points of 1 and 3 months, IVDs were collected and cells were analyzed for cell viability (fluorescence-activated cell sorting). The lapine IVDs were collected and examined for presence of cells positive for iron deposits using Berliner blue staining. Differentiation of the iron sucrose-labeled MSCs into adipogenic (lipid droplets), osteogenic (calcium deposits), and chondrogenic lineage (proteoglycan/collagen II accumulation) (3/3 donors) was observed in vitro. After transplantation, the mean cell viability for iron-labeled MSCs/IVD cells was 99%, for nonlabeled MSCs/IVD cells was 95%, and for control IVD cells was 99% at a time point of 1 month. At a time point of 3 months, mean cell viability was 73% for iron sucrose-labeled MSCs/IVD cells, for nonlabeled MSCs/IVD cells was 77%, and for control IVD cells was 98%. At the time point of 1 month, cells positive for iron deposits were detected sparsely distributed in IVDs (tissue sections) in 4/4 animals and at the time point of 3 months in 4/4 animals. The results indicate that iron sucrose can be used as a cell tracer with a stable detection potential in tissues (histologies). This may be an important evaluation tool for understanding stem cell distribution/function after transplantation into degenerated cartilaginous tissues.

[1]  J. Dobson,et al.  An in vitro model of mesenchymal stem cell targeting using magnetic particle labelling , 2015, Journal of tissue engineering and regenerative medicine.

[2]  D. Brat,et al.  Cancer stem cell division: when the rules of asymmetry are broken. , 2015, Stem cells and development.

[3]  G. Jenkin,et al.  Mesenchymal stem cell tracking in the intervertebral disc. , 2015, World journal of stem cells.

[4]  P. Parejiya,et al.  Physicochemical and structural characterization of iron–sucrose formulations: a comparative study , 2014, Pharmaceutical development and technology.

[5]  C. Brantsing,et al.  Cell viability and chondrogenic differentiation capability of human mesenchymal stem cells after iron labeling with iron sucrose. , 2014, Stem cells and development.

[6]  M. Dezawa,et al.  Mesenchymal Stem Cells and Their Subpopulation, Pluripotent Muse Cells, in Basic Research and Regenerative Medicine , 2014, Anatomical record.

[7]  A. E. El Haj,et al.  Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells – a rheumatoid arthritis mouse model , 2013, Stem Cell Research & Therapy.

[8]  A. Lindahl,et al.  Similar cellular migration patterns from niches in intervertebral disc and in knee-joint regions detected by in situ labeling: an experimental study in the New Zealand white rabbit , 2013, Stem Cell Research & Therapy.

[9]  D. Lane,et al.  Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. , 2013, Antioxidants & redox signaling.

[10]  Y. Qi,et al.  The application of super paramagnetic iron oxide-labeled mesenchymal stem cells in cell-based therapy , 2013, Molecular Biology Reports.

[11]  A. E. El Haj,et al.  Orthopaedic applications of nanoparticle-based stem cell therapies , 2012, Stem Cell Research & Therapy.

[12]  Ali S. Arbab,et al.  Self-Assembling Nanocomplexes by combining Ferumoxytol, Heparin And Protamine For Cell Tracking by MRI , 2011, Nature Medicine.

[13]  A. Lindahl,et al.  Human Disk Cells from Degenerated Disks and Mesenchymal Stem Cells in Co-Culture Result in Increased Matrix Production , 2009, Cells Tissues Organs.

[14]  Wei Liu,et al.  Detection and quantification of magnetically labeled cells by cellular MRI. , 2009, European journal of radiology.

[15]  A. Weinfeld,et al.  Hemosiderin estimations and sideroblast counts in the differential diagnosis of iron deficiency and other anemias. , 2009, Acta medica Scandinavica.

[16]  S. Koelling,et al.  Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. , 2009, Cell stem cell.

[17]  Liu Yang,et al.  In vivo MR imaging tracking of magnetic iron oxide nanoparticle labeled, engineered, autologous bone marrow mesenchymal stem cells following intra-articular injection. , 2008, Joint, bone, spine : revue du rhumatisme.

[18]  A. Ho,et al.  The Stromal Activity of Mesenchymal Stromal Cells , 2008, Transfusion Medicine and Hemotherapy.

[19]  P. Wielopolski,et al.  Effects of iron oxide incorporation for long term cell tracking on MSC differentiation in vitro and in vivo. , 2008, Biochemical and biophysical research communications.

[20]  Peter M Jakob,et al.  Iron oxide labelling of human mesenchymal stem cells in collagen hydrogels for articular cartilage repair. , 2008, Biomaterials.

[21]  J. Knoblich,et al.  Mechanisms of Asymmetric Stem Cell Division , 2008, Cell.

[22]  Ø. Kolbjørnsen,et al.  Calcification of intervertebral discs in the dachshund: a radiographic and histopathologic study of 20 dogs , 2007, Acta veterinaria Scandinavica.

[23]  C. Brantsing,et al.  Differentiation of human mesenchymal stem cells and articular chondrocytes: Analysis of chondrogenic potential and expression pattern of differentiation‐related transcription factors , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[24]  J. Cangiano,et al.  Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[25]  P. Ljungman,et al.  Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  Jeff W M Bulte,et al.  Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis , 2004, NMR in biomedicine.

[27]  F. Barry Biology and clinical applications of mesenchymal stem cells. , 2003, Birth defects research. Part C, Embryo today : reviews.

[28]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  U. Bahner,et al.  A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  A I Caplan,et al.  In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. , 1998, Experimental cell research.

[31]  S. Fowler,et al.  Application of Nile red, a fluorescent hydrophobic probe, for the detection of neutral lipid deposits in tissue sections: comparison with oil red O. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  R. Horobin,et al.  Surface staining of cartilage by Alcian Blue, with reference to the role of microscopic dye aggregates in histological staining , 1974, The Histochemical Journal.

[33]  J. Scott,et al.  The chemical and histochemical properties of Alcian Blue , 1964, Histochemie.

[34]  Wiendelt Steenbergen,et al.  Evaluation of superparamagnetic iron oxide nanoparticles (Endorem®) as a photoacoustic contrast agent for intra-operative nodal staging. , 2013, Contrast media & molecular imaging.

[35]  M. Kassem,et al.  Human mesenchymal stem cells: from basic biology to clinical applications , 2008, Gene Therapy.

[36]  P. Charbord,et al.  Culture and characterization of human bone marrow mesenchymal stem cells. , 2007, Methods in molecular medicine.

[37]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[38]  D. Jarocha,et al.  Mesenchymal stem cells: characteristics and clinical applications. , 2006, Folia histochemica et cytobiologica.

[39]  F. Marini,et al.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.